Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record.

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C†

Open access
Iwasaki, Yoshiaki, Ikeda, Hiroshi, Araki, Yasuyuki, Osawa, Toshiya, Kita, Keiji, Ando, Masaharu, Shimoe, Toshinari, Takaguchi, Kouichi, Hashimoto, Noriaki, Kobatake, Toshitsugu, Tomita, Minoru, Kawaguchi, Mitsuhiko, Kobashi, Haruhiko, Sakaguchi, Kohsaku, Shiratori, Yasushi · 2006 · Hepatology

Abstract

In contrast to the United States, Japanese patients with chronic hepatitis C currently treated with interferon are generally 10 to 15 years older. Older patients, however, tend to experience more frequent adverse events. This study was conducted to clarify the effect of patient age on the efficacy and safety of combination therapy. We consecutively enrolled 208 patients with naïve chronic hepatitis C. Patients were classified into three groups according to age: younger than 50 years of age (n = 52); 50 to 59 years old (n = 83); and 60 years of age or older (n = 73). Interferon alpha-2b therapy was administered daily for 2 weeks, followed by 3 times per week for 22 weeks, while ribavirin was administered daily. Of the 208 study patients, discontinuation of therapy or dose reduction was required in 116 (56%) and was more frequent in older patient groups: 38%, 48%, and 77% for the < 50, 50-59, and > or = 60-year-old patient groups, respectively (P < .001). Multivariate analysis showed patient age to be independently associated with adherence to therapy. A sustained virological response was achieved in 77 (37%) patients, with genotype, viral load, and adherence to therapy associated with this achievement. A tendency toward a lower sustained virological response rate was seen in the older patients. In conclusion, patient age is an important factor contributing to the safety of combination therapy. Thus, treatment schedule should be modified, or other therapeutic modalities should be considered for older patients with chronic hepatitis C.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.20984

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 170

Metadata

Authors
Iwasaki, Y., Ikeda, H., Araki, Y., Osawa, T., Kita, K., Ando, M., Shimoe, T., Takaguchi, K., Hashimoto, N., Kobatake, T., Tomita, M., Kawaguchi, M., Kobashi, H., Sakaguchi, K., & Shiratori, Y.
Venue
Hepatology
Published
2006-01
Volume
43
Issue
1
Pages
54-63
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2050629679
Cited by
170
References
0
FWCI
5.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C†. https://app.cochat.ai/papers/10.1002/hep.20984
The paper
Iwasaki, Y., Ikeda, H., Araki, Y., Osawa, T., Kita, K., Ando, M., Shimoe, T., Takaguchi, K., Hashimoto, N., Kobatake, T., Tomita, M., Kawaguchi, M., Kobashi, H., Sakaguchi, K., & Shiratori, Y. (2006). Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C†. Hepatology. https://doi.org/10.1002/hep.20984

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.